PTPRC and colitis: As expected, control Tregs prevented the development of colitis in recipient mice, but Esrrg-cKO Treg recipients showed a decreased body weight (Figure 2E) as well as an increased infiltration of CD45+ immune cells in the colon (Figure 2, F and G).